DOV, Merck Partner In $455M Deal Focused On Depression Aug. 9, 2004 DOV Pharmaceutical Inc. licensed worldwide rights of its triple uptake inhibitor compounds for psychiatric disorders to Merck & Co. Inc. in a deal worth $455 million, if all milestones are met. (BioWorld Today)Read More
Collaborations Between Biotechnology Companies And Universities/Nonprofit Institutions: May 20 - Aug. 5, 2004 Aug. 9, 2004
RSS